September 23, 2011
by admin
4 Comments
Across the whole sector, the return on investment in biotech (broadly defined to encompass diagnostic and medical device companies, as well as therapeutic developers) is poor, whether you look at publically traded stocks or private investments through venture capital funds. … Continue reading
September 11, 2011
by admin
2 Comments
Several very senior pharma executives were recently overheard by a journalist discussing what each of them viewed as the most important changes in the way healthcare will be delivered over the coming decade. Each of them listed several such factors, … Continue reading
September 4, 2011
by admin
1 Comment
As high stakes battles go, the 20-year competition between the various marketed statins in the cholesterol-lowering indication has been one of the most fascinating, and commercially important, in the history of the pharmaceutical industry. The prize is the largest annual … Continue reading